Lazard Asset Management
ARQT icon

Lazard Asset Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Lazard Asset Management’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.64M Buy
154,566
+61,212
+66% +$1.56M 0.01% 665
2025
Q4 		$2.71M Sell
93,354
-186,265
-67% -$4.77M ﹤0.01% 748
2025
Q3 		$5.27M Sell
279,619
-106,392
-28% -$1.68M 0.01% 569
2025
Q2 		$5.41M Buy
386,011
+11,928
+3% +$167K 0.01% 711
2025
Q1 		$5.85M Sell
374,083
-14,230
-4% -$200K 0.01% 633
2024
Q4 		$5.41M Sell
388,313
-414,891
-52% -$4.55M 0.01% 622
2024
Q3 		$7.47M Buy
803,204
+443,207
+123% +$4.37M 0.01% 533
2024
Q2 		$3.35M Buy
+359,997
New +$3.26M ﹤0.01% 771

Other funds holding ARQT

SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $22.9B AUM 115.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return